First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer

@article{Koehne2011FirstlinePP,
  title={First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer},
  author={C L Koehne and Ralf-Dieter Hofheinz and Laurent Mineur and Henry Letocha and Richard Greil and Josef Thaler and Eva Fernebro and Erick Gamelin and L Decosta and Meinolf Karthaus},
  journal={Journal of Cancer Research and Clinical Oncology},
  year={2011},
  volume={138},
  pages={65-72}
}
Panitumumab monotherapy is approved for KRAS wild-type (WT) metastatic colorectal cancer (mCRC) progressing after standard chemotherapy. This study evaluated first-line panitumumab plus FOLFIRI in patients with mCRC. In this phase II, single-arm study, panitumumab (6 mg/kg) and FOLFIRI [irinotecan (180 mg/m2) and leucovorin (400 mg/m2) followed by a 5-fluorouracil 400 mg/m2 bolus and a 2,400–3,000 mg/m2 continuous infusion] were administered every 14 days until progression. Data were analysed… CONTINUE READING